New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma

New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma

Today, it is difficult to overestimate the new directions in the pharmacotherapy of peripheral T-cell lymphomas (PTCL): immunotherapy, including adoptive, targeted therapy and chemotherapy. However, there are few biomarkers that predict response to therapy. A big problem is patients with refractory...

Descrición completa

Detalles Bibliográficos
Main Authors:	M. А. Sorokina, A. V. Rakhteenko, T. R. Grishina
Formato:	Artigo
Idioma:	Russian
Publicado:	IRBIS LLC 2023-07-01
Series:	Фармакоэкономика
Subjects:	peripheral t cell lymphoma azacitidine duvelisib romidepsin bortezomib biomarkers personalized medicine
Acceso en liña:	https://www.pharmacoeconomics.ru/jour/article/view/807

Títulos similares

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
por: Francine Foss, et al.
Publicado: (2016-03-01)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
por: Cinzia Pellegrini, et al.
Publicado: (2016-04-01)

MYCOSIS FUNGOIDES PROGRESSING TO PERIPHERAL T-CELL LYMPHOMA AND THE POTENTIAL ROLE OF ROMIDEPSIN THERAPY
por: Bengisu Ece Duman, et al.
Publicado: (2024-12-01)

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
por: Guang Lu, et al.
Publicado: (2023-08-01)

Interleukin-6 mediates resistance to PI3K-pathway–targeted therapy in lymphoma
por: Joo Hyun Kim, et al.
Publicado: (2019-10-01)

Antitumor effects of duvelisib on Epstein–Barr virus‐associated lymphoma cells
por: Jun‐ichi Kawada, et al.
Publicado: (2018-04-01)

Peripheral T-cell lymphomas: A review of current approaches and hopes for the future.
por: Alan Pierre Skarbnik, et al.
Publicado: (2013-05-01)

Recalcitrant Subcutaneous Panniculitis-Like T-Cell Lymphoma Responsive to Histone Deacetylase Inhibitor
por: Laura Gleason, et al.
Publicado: (2022-12-01)

Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma
por: Sabrina Manni, et al.
Publicado: (2021-10-01)

Prognosis and new therapeutic approaches in chronic lymphocytic leukemia treatment
por: Otašević Vladimir, et al.
Publicado: (2019-01-01)

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
por: Lorenzo Falchi, et al.
Publicado: (2016-11-01)

Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
por: S. S. Bessmeltsev, et al.
Publicado: (2022-11-01)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
por: Cesar Gentille, et al.
Publicado: (2022-07-01)

Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach
por: Waleed Sabry, et al.
Publicado: (2022-07-01)

Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions
por: Rozalyn L. Rodwin, et al.
Publicado: (2022-03-01)

Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
por: S. V. Semochkin, et al.
Publicado: (2022-04-01)

Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis
por: Shi-jun Li, et al.
Publicado: (2020-02-01)

Managing treatment-related peripheral neuropathy in patients with multiple myeloma
por: Grammatico S, et al.
Publicado: (2016-06-01)

Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy
por: Wilson Andrew J, et al.
Publicado: (2012-04-01)

Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy
por: Jeter Ashley, et al.
Publicado: (2012-08-01)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani Pier, et al.
Publicado: (2012-10-01)

Goshajinkigan reduces bortezomib-induced mechanical allodynia in rats: Possible involvement of kappa opioid receptor
por: Hitomi Higuchi, et al.
Publicado: (2015-11-01)

Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1
por: Xiang Zhou, et al.
Publicado: (2023-05-01)

Proteasome inhibitors prevent tumor cell proliferation in HHV-8-unrelated PEL-like lymphoma
por: Kiyotaka Kawauchi, et al.
Publicado: (2025-01-01)

An unusual case of plasmablastic lymphoma presenting as dermatomyositis
por: Ashlyn Rui Yin Chee, et al.
Publicado: (2020-05-01)

MALT Lymphoma Presenting with Peripheral Ulcerative Keratitis
por: Patil S, et al.
Publicado: (2022-09-01)

A clinical case of the effective combined use of BCL-2 and PI3K inhibitors in the treatment of a patient with an unfavorable chronic lymphocytic leukemia with transformation into diffuse large B-cell lymphoma (Richter’s syndrome)
por: O. A. Rukavitsyn, et al.
Publicado: (2022-11-01)

Peripheral T cell lymphoma: Not otherwise specified
por: Anusha H Pai, et al.
Publicado: (2015-01-01)

Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin
por: Tatsuro Jo, et al.
Publicado: (2020-11-01)

Peripheral T-cell lymphoma: Frequency and distribution in a tertiary referral center in South India
por: Deepak K Burad, et al.
Publicado: (2012-01-01)

Editorial: Challenges in peripheral T-cell lymphomas: from biological advances to clinical applicability
por: Luís Alberto de Pádua Covas Lage, et al.
Publicado: (2023-12-01)

Correlation of serum metabolites and clinical features in patients with peripheral T-cell lymphoma
por: DUAN Yishuo, et al.
Publicado: (2024-02-01)

Peripheral T-cell lymphoma, not otherwise specified
por: Kunal Kishor Jha, et al.
Publicado: (2017-01-01)

Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
por: N. V. Stepanova, et al.
Publicado: (2022-11-01)

Unspecified skin peripheral T-cell lymphoma: diagnostic difficulties
por: O. Yu. Olisova, et al.
Publicado: (2020-10-01)

Frequency, distribution, and immunomorphologic characteristics of peripheral T-cell lymphoma, not otherwise specified in a tertiary care center in Southern India
por: Archana Lakshmanan, et al.
Publicado: (2018-01-01)

Therapeutic options in peripheral T cell lymphoma
por: Yaping Zhang, et al.
Publicado: (2016-04-01)

Outcome in patients with peripheral T-cell lymphoma treated with pralatrexate, single center experience
por: Aydan Akdeniz, et al.
Publicado: (2022-01-01)

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA
por: Simon Heine, et al.
Publicado: (2018-09-01)

Peripheral T-Cell Lymphomas of the T Follicular Helper Type: Clinical, Pathological, and Genetic Attributes
por: Karthik A. Ganapathi, et al.
Publicado: (2022-03-01)